Home treatment device may improve visual acuity in children with amblyopia



Yehezkel O, et al. A pivotal prospective, multicenter, randomized, masked, controlled trial to assess the safety and efficacy of an eye tracking-based treatment for amblyopia under binocular versus patch conditions – interim results. Presented at the Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Yehezkel declares to be employed by NovaSight.

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

DENVER — Children with amblyopia treated with a home device experienced improved visual acuity and binocularity, according to a study presented at the Association for Research in Vision and Ophthalmology meeting.

Oren Yehezkel, PhD, reported data from a pivotal randomized controlled trial that compared the CureSight (NovaSight) eye-tracking-based device to the patch in children with amblyopia.

Oren Yehezkel

“Other studies have shown that patch compliance is around 50%,” he told Healio/OSN. “Kids tend not to like the patch. This [device] gives them the ability to watch whatever they want on the Internet.

CureSight separates the content into two channels and blurs the central vision of the normal eye. Yehezkel said the device encourages children to use both eyes.

One hundred children with amblyopia were randomly assigned to treatment with the CureSight device or a patch for the 16-week study. The primary endpoint was non-inferiority of improvement in corrected visual acuity in the amblyopic eye at 16 weeks. Improvements in binocular visual acuity and stereoacuity, as well as compliance and satisfaction, were also recorded.

Yehezkel said the device met the primary endpoint of noninferiority and the improvement in distance visual acuity in the amblyopic eye was greater in the CureSight group than in the patch group at week 16. Improvement in binocular visual acuity was also greater in the CureSight group.

Participants in the CureSight group had higher average adherence at 16 weeks, and 93% of parents said they were likely or very likely to choose CureSight over the patch.

“The average adhesion was 95% versus just 79% for the patch, so that was a lot higher,” Yehezkel said. “Kids tend to like it because they can see anything they want.”

Briana R. Cross